ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

34 links0 made here, not in the record64 judgments2 judges (the rules as one: Rule based)0 record changes seen
Claude Opus 5.5Rule based
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05582499Fudan University ShanghaiCancer Center Breast CancerPrecision Platform SeriesStudy- Neoadjuvant TherapyFudan UniversityPhase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSBreast NeoplasmsThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.Triple Negative Breast Neop…The registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSDalpiciclibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPyrotinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTrastuzumab rezetecanEntry “SHR-A1811”, read by our name r…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAdebrelimabEntry “SHR-1316”, read by our name ru…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCamrelizumabIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTizetatug rezetecanEntry “SHR-A1921”, read by our name r…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPertuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTrastuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedGoserelinIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedLetrozoleIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAlbumin-Bound PaclitaxelEntry “Nab paclitaxel”, read by our n…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCarboplatinIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedEpirubicinIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCyclophosphamideIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedFluzoparibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedApatinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedFamitinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedDocetaxelEntry “HB1801”, read by our name rule›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAnti-HER2/Topoisomerase I I…Entry “TQB2102”, read by our name rule›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedBenmelstobartIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundAnlotinibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundAnti-PD-1/Anti-TGF-beta Bif…Entry “TQB2868”, read by our name rule›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedIvonescimabIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAnti-PD-1/Anti-VEGF Bispeci…Entry “JS207”, read by our name rule›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAnbenitamab repodatecanEntry “JSKN003”, read by our name rule›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedHRS-4508Intervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedSHR-4602Intervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPaclitaxelIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedHRS-6209Intervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedBulumtatug fuvedotinEntry “9MW2821”, read by our name rule›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundAnti-HER2 Antibody-drug Con…Entry “IBI354”, read by our name rule›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAtezolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · Not givenNot given

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Dalpiciclib

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Dalpiciclib”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2DalpiciclibClaude Opus 5.5TestedCurrent
Nov 2PyrotinibClaude Opus 5.5TestedCurrent
Nov 2Trastuzumab rezetecanClaude Opus 5.5TestedCurrent
Nov 2AdebrelimabClaude Opus 5.5TestedCurrent
Nov 2CamrelizumabClaude Opus 5.5TestedCurrent
Nov 2Tizetatug rezetecanClaude Opus 5.5TestedCurrent
Nov 2PertuzumabClaude Opus 5.5TestedCurrent
Nov 2TrastuzumabClaude Opus 5.5TestedCurrent
Nov 2GoserelinClaude Opus 5.5TestedCurrent
Nov 2LetrozoleClaude Opus 5.5TestedCurrent
Nov 2Albumin-Bound PaclitaxelClaude Opus 5.5TestedCurrent
Nov 2CarboplatinClaude Opus 5.5TestedCurrent
Nov 2EpirubicinClaude Opus 5.5TestedCurrent
Nov 2CyclophosphamideClaude Opus 5.5TestedCurrent
Nov 2FluzoparibClaude Opus 5.5TestedCurrent
Nov 2ApatinibClaude Opus 5.5TestedCurrent
Nov 2FamitinibClaude Opus 5.5TestedCurrent
Nov 2DocetaxelClaude Opus 5.5TestedCurrent
Nov 2Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Claude Opus 5.5TestedCurrent
Nov 2BenmelstobartClaude Opus 5.5BackgroundCurrent
Nov 2AnlotinibClaude Opus 5.5BackgroundCurrent
Nov 2Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Claude Opus 5.5TestedCurrent
Nov 2IvonescimabClaude Opus 5.5TestedCurrent
Nov 2Anti-PD-1/Anti-VEGF Bispecific Antibody JS207Claude Opus 5.5TestedCurrent
Nov 2Anbenitamab repodatecanClaude Opus 5.5TestedCurrent
Nov 2HRS-4508Claude Opus 5.5TestedCurrent
Nov 2SHR-4602Claude Opus 5.5TestedCurrent
Nov 2PaclitaxelClaude Opus 5.5TestedCurrent
Nov 2HRS-6209Claude Opus 5.5TestedCurrent
Nov 2Bulumtatug fuvedotinClaude Opus 5.5BackgroundCurrent
Nov 2Anti-HER2 Antibody-drug Conjugate IBI354Claude Opus 5.5TestedCurrent
Nov 2AtezolizumabClaude Opus 5.5Not givenCurrent
Nov 18DalpiciclibRule based · role ruleTestedAgrees
Nov 18PyrotinibRule based · role ruleTestedAgrees
Nov 18Trastuzumab rezetecanRule based · role ruleTestedAgrees
Nov 18AdebrelimabRule based · role ruleTestedAgrees
Nov 18CamrelizumabRule based · role ruleTestedAgrees
Nov 18Tizetatug rezetecanRule based · role ruleTestedAgrees
Nov 18PertuzumabRule based · role ruleTestedAgrees
Nov 18TrastuzumabRule based · role ruleTestedAgrees
Nov 18GoserelinRule based · role ruleTestedAgrees
Nov 18LetrozoleRule based · role ruleTestedAgrees
Nov 18Albumin-Bound PaclitaxelRule based · role ruleTestedAgrees
Nov 18CarboplatinRule based · role ruleTestedAgrees
Nov 18EpirubicinRule based · role ruleTestedAgrees
Nov 18CyclophosphamideRule based · role ruleTestedAgrees
Nov 18FluzoparibRule based · role ruleTestedAgrees
Nov 18ApatinibRule based · role ruleTestedAgrees
Nov 18FamitinibRule based · role ruleTestedAgrees
Nov 18DocetaxelRule based · role ruleTestedAgrees
Nov 18Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Rule based · role ruleTestedAgrees
Nov 18BenmelstobartRule based · role ruleBackgroundAgrees
Nov 18AnlotinibRule based · role ruleBackgroundAgrees
Nov 18Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Rule based · role ruleTestedAgrees
Nov 18IvonescimabRule based · role ruleTestedAgrees
Nov 18Anti-PD-1/Anti-VEGF Bispecific Antibody JS207Rule based · role ruleTestedAgrees
Nov 18Anbenitamab repodatecanRule based · role ruleTestedAgrees
Nov 18HRS-4508Rule based · role ruleTestedAgrees
Nov 18SHR-4602Rule based · role ruleTestedAgrees
Nov 18PaclitaxelRule based · role ruleTestedAgrees
Nov 18HRS-6209Rule based · role ruleTestedAgrees
Nov 18Bulumtatug fuvedotinRule based · role ruleBackgroundAgrees
Nov 18Anti-HER2 Antibody-drug Conjugate IBI354Rule based · role ruleTestedAgrees
As of nowTriple Negative Breast NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.